🇺🇸 FDA
Pipeline program

Fruquintinib Combined With Chemotherapy

PRO00039815 (HMCC-GI25-001)

Phase 2 small_molecule active

Quick answer

Fruquintinib Combined With Chemotherapy for Metastatic Colorectal Cancer (CRC) is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Metastatic Colorectal Cancer (CRC)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials